HPC7
MCID: PRS080
MIFTS: 28

Prostate Cancer, Hereditary, 7 (HPC7)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 7

MalaCards integrated aliases for Prostate Cancer, Hereditary, 7:

Name: Prostate Cancer, Hereditary, 7 57 13 73
Prostate Cancer Aggressiveness 57
Hpc7 57

Classifications:



External Ids:

OMIM 57 610321
MedGen 42 C1853195
UMLS 73 C1853195

Summaries for Prostate Cancer, Hereditary, 7

MalaCards based summary : Prostate Cancer, Hereditary, 7, also known as prostate cancer aggressiveness, is related to prostate cancer aggressiveness quantitative trait locus on chromosome 19 and prostate cancer. An important gene associated with Prostate Cancer, Hereditary, 7 is HPC7 (Prostate Cancer, Hereditary, 7). The drugs Olaparib and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include prostate and bone.

Description from OMIM: 610321

Related Diseases for Prostate Cancer, Hereditary, 7

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 7

Clinical features from OMIM:

610321

Drugs & Therapeutics for Prostate Cancer, Hereditary, 7

Drugs for Prostate Cancer, Hereditary, 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olaparib Approved Phase 2 763113-22-0 23725625
2
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
3
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
4
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
5 Lycopene Approved, Investigational Phase 2 502-65-8 446925
6
Tocopherol Approved, Investigational Phase 2 1406-66-2 14986
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
8
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
9
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
10
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
11 Tocotrienol Investigational Phase 2 6829-55-6
12 Antineoplastic Agents, Hormonal Phase 2
13 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
14 Hormone Antagonists Phase 2
15 Hormones Phase 2
16 glucocorticoids Phase 2
17 Anti-Inflammatory Agents Phase 2
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
19 Antioxidants Phase 2
20 Trace Elements Phase 2
21 Micronutrients Phase 2
22 Tocotrienols Phase 2
23 Ergocalciferols Phase 2
24 Carotenoids Phase 2
25 Radiation-Protective Agents Phase 2
26 Calciferol Phase 2
27 Tea Phase 2
28 Vitamins Phase 2
29 Tocopherols Phase 2
30 Vitamin D2 Phase 2
31 Protective Agents Phase 2
32 Bone Density Conservation Agents Phase 2
33 Immunologic Factors
34 Antigen-Antibody Complex
35 Immunoglobulins
36 Antibodies

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Recruiting NCT03263650 Phase 2 Cabazitaxel;Carboplatin;Prednisone 5Mg;Olaparib
2 Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer Completed NCT00844792 Phase 2 Placebo
3 Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness Unknown status NCT02545881
4 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Recruiting NCT01464216
5 Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness Completed NCT03289130
6 Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial Recruiting NCT03413007
7 Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer Recruiting NCT02745496 Not Applicable
8 Structural Network on Prostate Cancer in the French Greater West Region Recruiting NCT03214315
9 Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer Completed NCT01780701
10 Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla Active, not recruiting NCT00588679 Not Applicable
11 Biobank for African American Prostate Cancer Research in Florida Recruiting NCT03232411

Search NIH Clinical Center for Prostate Cancer, Hereditary, 7

Genetic Tests for Prostate Cancer, Hereditary, 7

Anatomical Context for Prostate Cancer, Hereditary, 7

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 7:

41
Prostate, Bone

Publications for Prostate Cancer, Hereditary, 7

Articles related to Prostate Cancer, Hereditary, 7:

(show top 50) (show all 127)
# Title Authors Year
1
Oncogenic regulatory circuits driven by 19q13 rs11672691 underlies prostate cancer aggressiveness. ( 30525094 )
2018
2
Impact of adipose tissue on prostate cancer aggressiveness - analysis of a high-risk population. ( 30471220 )
2018
3
Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density. ( 30297390 )
2018
4
Fatty acid profile in peri-prostatic adipose tissue and prostate cancer aggressiveness in African-Caribbean and Caucasian patients. ( 29413967 )
2018
5
Low-dose statin treatment increases prostate cancer aggressiveness. ( 29416709 )
2018
6
Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue. ( 29581441 )
2018
7
Periprostatic Fat Adipokines Expression Correlated with Prostate Cancer Aggressiveness in Men Undergoing Radical Prostatectomy for Clinically Localised Disease. ( 29969844 )
2018
8
The Nucleoporin POM121 Enhances Prostate Cancer Aggressiveness. ( 30120114 )
2018
9
The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. ( 30267174 )
2018
10
The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. ( 28851363 )
2017
11
Normalized periprostatic fat MRI measurements can predict prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localised disease. ( 28680067 )
2017
12
Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. ( 28039468 )
2017
13
T2-weighted MRI-derived textural features reflect prostate cancer aggressiveness: preliminary results. ( 27975146 )
2017
14
Observed correlation between the expression levels of catalytic subunit, CI^2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness. ( 27838142 )
2017
15
Apparent diffusion coefficient values are superior to transrectal ultrasound-guided prostate biopsy for the assessment of prostate cancer aggressiveness. ( 27055916 )
2017
16
Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project. ( 27595916 )
2017
17
Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. ( 27842896 )
2017
18
The role of GATA2 in lethal prostate cancer aggressiveness. ( 27872477 )
2017
19
Re: Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index: C. Stephan, M. Lein, J. Matalon, E. Kilic, Z. Zhao, J. Busch and K. Jung J Urol 2016;196:709-714. ( 27992743 )
2017
20
A novel non-canonical Wnt signature for prostate cancer aggressiveness. ( 28030815 )
2017
21
Assessment of prostate cancer aggressiveness using apparent diffusion coefficient values: impact of patient race and age. ( 28161826 )
2017
22
A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness. ( 28346484 )
2017
23
Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion. ( 28428273 )
2017
24
Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. ( 28445145 )
2017
25
Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists' recommendations for active treatment or active surveillance: a randomized clinical utility trial. ( 28673277 )
2017
26
Kallikreins Panel for Prostate Cancer Aggressiveness Prediction: More Is Not Enough. ( 28720353 )
2017
27
Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness. ( 28981526 )
2017
28
Evaluation of Peripheral Zone Prostate Cancer Aggressiveness Using the Ratio of Diffusion Tensor Imaging Measures. ( 29097929 )
2017
29
Automatic Detection and Quantitative DCE-MRI Scoring of Prostate Cancer Aggressiveness. ( 29177134 )
2017
30
Trinucleotide repeat length in the first exon of the androgen receptor gene may be associated with prostate carcinogenesis and facilitate prediction of prostate cancer aggressiveness. ( 26895311 )
2016
31
Core 2 I^-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness. ( 26768364 )
2016
32
Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population. ( 26754263 )
2016
33
Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness? ( 26210155 )
2016
34
Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolina-Louisiana Prostate Cancer Project. ( 26819265 )
2016
35
Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study. ( 26847416 )
2016
36
Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. ( 26847995 )
2016
37
Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI. ( 26900904 )
2016
38
Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index. ( 26976204 )
2016
39
Preoperative Evaluation of Prostate Cancer Aggressiveness: Using ADC and ADC Ratio in Determining Gleason Score. ( 27077643 )
2016
40
Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP). ( 27271547 )
2016
41
Transcriptome profiling links the intrinsic properties of human prostate basal cells to prostate cancer aggressiveness. ( 27314102 )
2016
42
Influence of adipocytokines in periprostatic adipose tissue on prostate cancer aggressiveness. ( 27371773 )
2016
43
The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. ( 27830399 )
2016
44
Contrast-enhanced transrectal ultrasound for prediction of prostate cancer aggressiveness: The role of normal peripheral zone time-intensity curves. ( 27929134 )
2016
45
Association of genetic polymorphisms in the telomerase reverse transcriptase gene with prostate cancer aggressiveness. ( 25738283 )
2015
46
Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. ( 25595908 )
2015
47
Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T. ( 24504488 )
2015
48
A better understating of the morphological features and molecular characteristics of intraductal carcinoma helps clinicians further explain prostate cancer aggressiveness. ( 25194910 )
2015
49
Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. ( 25307492 )
2015
50
MRS measured fatty acid composition of periprostatic adipose tissue correlates with pathological measures of prostate cancer aggressiveness. ( 25522916 )
2015

Variations for Prostate Cancer, Hereditary, 7

Expression for Prostate Cancer, Hereditary, 7

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 7.

Pathways for Prostate Cancer, Hereditary, 7

GO Terms for Prostate Cancer, Hereditary, 7

Sources for Prostate Cancer, Hereditary, 7

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....